Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial
Authors:
- 1 December 2017
- journal article
- research article
- Published by Elsevier in The American Journal of Medicine
- Vol. 130 (12) , 1440-1448.e1
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Insights Into Onco-CardiologyJACC, 2014
- Cancer drugs and the heart: importance and managementEuropean Heart Journal, 2012
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationaleAmerican Heart Journal, 2010
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009
- Effectiveness of Warfarin among Patients with CancerJournal of General Internal Medicine, 2007
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005
- Thromboembolic Events in the Cancer PatientJournal of Women's Health, 2003
- A Comparison of the Safety and Efficacy of Oral Antiocoagulation for the Treatment of Venous Thromboembolic Disease in Patients with or without MalignancyThrombosis and Haemostasis, 2000